Cancer is one of the most dangerous health problems of today modern societies which has an increasing rate especially in developing countries. There are many diverse ongoing treatment attempts trying to defeat cancer. Despite that, scientists have been unable to find a permanent cure for this disease. In many cases although there is a successful first response in patients, cancer cells are fina...

Acupuncture is increasingly used in patients with chronic pain, but there is a lack of evidence on the cost-benefit relationship of this treatment strategy. The objective of this study was to assess costs and cost-effectiveness of additional acupuncture treatment in patients with chronic neck pain compared to patients receiving routine care alone. A randomized controlled trial including patient...

• Payers report that it will be very difficult for high-cost targeted therapies to be included on the NRDL, although they are increasingly likely to be included in the PRDLs. The greatest problem is that the drugs are too expensive. CANCER TREATMENT IN CHINA: HOW ARE POLICY AND PRACTICE IN TIER 1 VERSUS TIER 2/3 CITIES IMPACTING PATIENT ACCESS TO HIGH-COST THERAPIES Authors: Michelle Zhou, M.B....

Background: Epidemiological studies are shown robust association between human papillomavirus (HPV) and cervical cancer. From 1990 HPV was known as a necessary but insufficient cause of cervical invasive cancer. The purpose of this study was to evaluate the cost effectiveness of HPV test in cervical cancer screening. Materials and Methods: This is a systematic review article; the newest scienti...

OBJECTIVES The aim of this study was to estimate lowest possible treatment costs for four novel cancer drugs, hypothesising that generic manufacturing could significantly reduce treatment costs. SETTING This research was carried out in a non-clinical research setting using secondary data. PARTICIPANTS There were no human participants in the study. Four drugs were selected for the study: bor...

Objectives: To assess the cost of monoclonal antibodies in an Athens/Greece tertiary hospital in a seven year cost comparison analysis and to compare results to other in-patent drug categories. Methods: In this 7-year study (2008-2014) monoclonal antibodies (MAbs) consumption in Evaggelismos hospital (931beds) was assessed. MAbs consumption/cost in hematology, oncology, rheumatology, gastroente...

BACKGROUND Many oncological drugs that are being used in the adjuvant setting were first submitted for reimbursement in the metastatic stage, with differences in incremental cost-effectiveness ratios (ICERs) in both settings having potential implications for reimbursement and pricing. The aim of this study is to identify a possible trend in the cost-effectiveness for the early/adjuvant and late...